Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SNY crawled date : 2022 - 12 - 15 save search
Optinose Appoints Paul Spence as Chief Commercial Officer
Published: 2022-12-15 (Crawled : 22:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 0
|
Health Technology
|
| O: -1.49%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 11K
|
Health Technology
|
| O: -2.35%
H: 0.0%
C: 0.0%
OPTN | $1.03 15.19% 7.28% 8.2K
|
Health Services
|
| O: -4.0%
H: 5.95%
C: 1.19%
commercial
Global Rare Disease Drugs Market Report 2022-2027: Increasing Focus on Research Activities and Development of Novel Therapeutic Drugs to Facilitate Future Growth
Published: 2022-12-15 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 0
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
TAK | News | $13.36 0.91% 0.0% 1.5M
|
Health Technology
|
| O: -0.71%
H: 0.07%
C: -1.05%
NVS | News | $95.12 0.81% 4.36% 160K
|
Health Technology
|
| O: -0.71%
H: 0.08%
C: -1.07%
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
|
| O: -0.59%
H: 0.44%
C: -0.48%
SNY | News | $47.15 1.84% 1.75% 11K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
rare research global disease report growth market
Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments
Published: 2022-12-15 (Crawled : 14:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 0
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 11K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
pharmaceuticals health
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
Published: 2022-12-15 (Crawled : 14:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 0
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 11K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ALNY | $145.79 0.96% 0.94% 2
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: -1.56%
day program
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
Published: 2022-12-15 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 0
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 11K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
REGN | News | $900.16 0.37% 0.32% 28
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: -2.26%
dupixent approved
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
Published: 2022-12-15 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 0
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 11K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
REGN | News | $900.16 0.37% 0.32% 28
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: -2.26%
dupixent approved
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone Everest Medicines announced that the company has achieved the preclinical proof-of-...
Published: 2022-12-15 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 0
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 11K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
PRTA 4 | $21.29 0.61% 0.56% 390K
|
Health Technology
|
| O: 0.97%
H: 7.04%
C: -0.02%
MTP | $0.4703 -70.79% -73.69% 0
|
Health Technology
|
| O: -4.03%
H: 2.0%
C: -15.78%
preclinical vaccine program mrna milestone
Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease
Published: 2022-12-15 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 0
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
LLY | News | $731.33 0.69% 0.73% 12K
|
Health Technology
|
| O: -0.78%
H: 0.92%
C: -0.18%
SNY | News | $47.15 1.84% 1.75% 11K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
INCY | $51.92 -0.82% -0.83% 180
|
Health Technology
|
| O: -0.83%
H: 0.66%
C: 0.3%
treatment disease collaboration
Sinusitis drugs market size to increase by USD 801.39 million: 40% growth to originate from North America - Technavio
Published: 2022-12-14 (Crawled : 00:00) - prnewswire.com
GLAXF | News | $20.305 0.52% -14.18% 0
|
Health Technology
|
| O: -1.57%
H: 2.23%
C: 2.23%
SNYNF | News | $92.7 -2.18% 0
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
NVS | News | $95.12 0.81% 4.36% 160K
|
Health Technology
|
| O: -0.71%
H: 0.08%
C: -1.07%
GSK | News | $40.59 2.11% 0.1% 1.3K
|
Health Technology
|
| O: 0.36%
H: 0.28%
C: -1.17%
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
|
| O: -0.59%
H: 0.44%
C: -0.48%
SNY | News | $47.15 1.84% 1.75% 11K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
america sinusitis growth market
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | $2.5 100.0% 58.33% 200M
|
Finance
EDBL | News | $6.26 66.49% 48.56% 270K
|
SMFL | $4.35 29.2% 47.55% 4.2M
|
Manufacturing
MLEC | $2.47 76.43% 38.05% 460K
|
n/a
PEGY | $0.0458 -10.2% 28.77% 79M
|
Manufacturing
PROK | $2.72 33.33% 26.88% 20K
|
PALI | $4.93 4.67% 25.83% 2.1M
|
Manufacturing
SGD | $0.685 -1.71% 22.48% 2M
|
n/a
SILO | $1.99 0.71% 20.64% 1.8M
|
Finance and Insurance
NNVC | $1.12 1.82% 19.64% 2.5K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.